Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe - Wikidata - awgldk - TriplyDB

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

http://www.wikidata.org/entity/Q33704930

about

Membrane transporters in drug development Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study Select cyclopentenone prostaglandins trigger glutathione efflux and the role of ABCG2 transport Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.The challenge of exploiting ABCG2 in the clinic.Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation.Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.Pharmacogenomic importance of ABCG2.The role of transporters in the pharmacokinetics of orally administered drugs.Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy Drug transport by breast cancer resistance protein.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study.Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity.Binding Performance of Human Intravenous Immunoglobulin and 20()-7-Ethylcamptothecin

P2860

Q29616802-48C5D051-57E6-4590-BC21-DF0FD407839C Q30907350-E8427B31-B331-4E84-9391-DEBE5107DFA0 Q33466591-4448F4F9-BF1A-425C-80F6-1A255A3A3906 Q33690892-EAAEBD37-A00C-44BB-920F-9AC496783B27 Q33714593-B8DB7C36-A2F4-4632-B132-73EB8D8D0861 Q33883496-3EE2EDF2-539D-47FD-91D5-13AAC7629A7C Q34774854-D4BDECDA-899A-4E2B-8603-B46CBE2E0755 Q34871636-6A08467A-41D2-4B09-9E77-61A1B1833367 Q34897883-1B85A413-FFD1-4628-98CC-8A17E5C811ED Q34968909-9771EE02-AE22-4786-9C71-17B90A9451F4 Q35141418-93CCC0A0-C14C-4CB9-AD4A-9CD9B8066983 Q35927508-7142E54E-9F88-43AF-8865-9A7C7322EE31 Q36245600-434BA4C6-256C-4438-9C95-EFDE92A93373 Q36733503-10521FC9-9ADC-4AA4-837A-BF754BBF4B24 Q37143617-42AB6AF9-6573-48EA-84AF-0E59307BF609 Q37235629-04F35EF0-8655-48D0-9EAE-2509F42DA521 Q37537018-7AB89CB5-8439-4E2E-8E52-85A7DB7FAFBE Q37735146-2ADC0D15-7139-44C2-A248-E951C0D334A3 Q37793056-D32487E0-543E-42B4-A901-679A2CEC628D Q38003174-F3038461-08DC-4B53-AE2F-A1700CC4C40A Q38038547-C3203DDD-184C-401A-B592-80D861556AC2 Q38051447-AC3CF68C-CF01-4F9D-BEEE-A19CA5988C46 Q38071700-0FCF0434-E1A2-41BC-989F-C2095E5FC9F0 Q38207943-9057E9C1-EA8E-4875-B168-28540BD084FD Q38243832-BDC1EC1A-7F12-4C3D-806D-9774031F830C Q38379295-7A6297BA-CB6A-4CF8-816E-69345D8F482D Q38730592-FBABD867-FB52-463F-A1F4-0F654FF8D20E Q39923958-7D8C95A8-A2CE-4C04-84A0-F05B0ADDEF79 Q41643368-0ADCD1A0-4C55-4970-B2DF-E42C9089CC89 Q42178200-E035F6A7-6EDD-4500-B851-ED88016197CA Q42512355-38331F5B-5FA7-4BF0-89B2-FA60BAC73980 Q43258273-E6081E57-C80C-4383-AF1E-D4DCFD4D6607 Q44737065-DF6AA6E5-83BC-4485-873C-8BAAB451021D Q45993642-769092FD-7055-4DBB-9BAC-EF49DDC307C0 Q48811919-1E5B60EA-B9AC-46CA-AA18-4D8D108E4E4E Q48893219-F5AA78CF-495B-41C0-B71A-6645B1490BD5 Q48899356-0E6E81F4-25CE-4D30-AE89-B3F8B8CA02FD Q51749326-4928A7DF-26E7-4D9A-AEBD-E1799360B557 Q58691864-4B0F14B3-C7CC-4073-BD5C-9109A8ECB10B

P2860

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

http://www.wikidata.org/entity/Q33704930

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Breast cancer resistance prote ...... fasalazine as an in vivo probe

@ast

Breast cancer resistance prote ...... fasalazine as an in vivo probe

@en

type

label

Breast cancer resistance prote ...... fasalazine as an in vivo probe

@ast

Breast cancer resistance prote ...... fasalazine as an in vivo probe

@en

prefLabel

Breast cancer resistance prote ...... fasalazine as an in vivo probe

@ast

Breast cancer resistance prote ...... fasalazine as an in vivo probe

@en

P1433

Q33704930-0236FB3C-793E-4DC9-B12C-CEED9BA313D9

P1476

Q33704930-0B409080-3754-4D8D-970C-9171BC835DF8

P2093

Q33704930-19C791D5-4AFD-4E7A-9FAF-FFE7BEA3F1B6

Q33704930-279A3F08-FC25-46DC-8830-7342BC47067C

Q33704930-38B43200-6256-4DD8-80C7-FBF9450C08A8

Q33704930-658A3F1E-CFB0-49DD-9B4E-89096B6689D5

Q33704930-8DCD0B52-08BC-4D00-8D4B-706E0264D484

Q33704930-A7FF4729-058A-417F-A9C6-717EC6C7A1B5

Q33704930-A82E0477-0F10-4F37-850D-5A609652890D

Q33704930-B139A9BE-4335-4031-BA2E-20A41CFBAEC4

Q33704930-CD56D953-0935-43D1-ABA4-38467DDF6CE7

Q33704930-DEEED7E9-1F73-4E85-8BF6-27FEF0DC01A4

P2860

Q33704930-06FB6F5F-8B7F-4896-9E46-E02AF8635AE5

Q33704930-18F5849B-25EE-46F7-823F-A0E4AFDEA9CA

Q33704930-24C4754E-0057-4C5F-8960-5AD0B9F48AF5

Q33704930-2EB6E703-2B7E-4483-9850-0D9049D4CA53

Q33704930-2F694ECB-551E-4779-B899-0D9E4F87F3D1

Q33704930-32F70EBD-5560-41AD-B10C-1AC095BCCC93

Q33704930-374F4C2F-CBE6-424E-9890-DBE2C8F93677

Q33704930-3B93FFD1-A300-4882-AE5D-74613A6C3951

Q33704930-5B120B05-040B-40A7-B620-B3E070B33687

Q33704930-5FA8E1E3-7DFB-423F-82A4-F8A81F2B28AC

P304

Q33704930-CD767C2C-147E-45FE-8F86-01D9FBC13376

P31

Q33704930-A76DD1E8-199C-4482-B358-B26DECEE0EF1

P356

Q33704930-EAACCF35-1DB6-48C3-BAE4-60BD1D919F6F

P433

Q33704930-50132F5F-C0F8-4B49-AFF4-2CA93FD8A330

P478

Q33704930-4A7385BB-601D-4D34-91AF-659E157B8181

P577

Q33704930-722E1B37-18EB-450B-9F7D-0AF55EE18A53

P698

Q33704930-F6E539A0-8D3D-48CC-B930-22D83382AA69

P932

Q33704930-49057543-4220-4BF4-80AB-8FEA92352F06

P356

FPC.0B013E3282F974DC

P1433

Pharmacogenetics and Genomics

P1476

Breast cancer resistance prote ...... fasalazine as an in vivo probe

@en

P2093

Bradley L Urquhart

http://www.w3.org/2001/XMLSchema#string

Brenda F Leake

http://www.w3.org/2001/XMLSchema#string

George K Dresser

http://www.w3.org/2001/XMLSchema#string

Hani Zaher

http://www.w3.org/2001/XMLSchema#string

Jamie C Gregor

http://www.w3.org/2001/XMLSchema#string

Joe Palandra

http://www.w3.org/2001/XMLSchema#string

Joseph A Ware

http://www.w3.org/2001/XMLSchema#string

Richard B Kim

http://www.w3.org/2001/XMLSchema#string

Richard H Ho

http://www.w3.org/2001/XMLSchema#string

Rommel G Tirona

http://www.w3.org/2001/XMLSchema#string

P2860

A multidrug resistance transporter from human MCF-7 breast cancer cells

Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart.

Localisation of breast cancer resistance protein in microvessel endothelium of human brain.

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

Breast cancer resistance protein (BCRP/ABCG2).

Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.

The role of half-transporters in multidrug resistance.

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

P304

439-448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E3282F974DC

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18408567

http://www.w3.org/2001/XMLSchema#string

P932

4043148

http://www.w3.org/2001/XMLSchema#string